Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA PR Newsw
ADMA - ADMA Biologics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$21.00
DETAILS
HIGH:
$24.00
LOW:
$18.00
MEDIAN:
$21.00
CONSENSUS:
$21.00
UPSIDE:
154.85%
Stock News
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
NEW YORK, May 23, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public. So What: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.
Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities laws.
Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026?
ADMA cuts 2026 guidance after weak Bivigam sales and IG market pressure weigh on revenues amid rising competition and order volatility.
ADMA Inquiry News: ADMA Biologics Investors are Notified of BFA Law's Ongoing Investigation into the Company's Potential Misstatements – Contact the Firm if You Lost Money
ADMA Biologics Investors are Notified of BFA Law's Ongoing Investigation into the Company's Potential Misstatements – Contact the Firm if You Lost Money
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.
ROSEN, A GLOBALLY RESPECTED LAW FIRM Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
New York, New York--(Newsfile Corp. - May 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ADMA Securities Investigation: ADMA Biologics 29% Stock Drop Triggers Securities Fraud Investigation Over Channel Stuffing Claims – Investors Urged to Contact BFA Law
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
ADMA shares plunge after the company cuts 2026 guidance, citing pricing pressure, rising competition and elevated IG channel inventories.
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
NEW YORK, May 18, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public. So What: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ADMA Fraud Notice: ADMA Biologics is being Investigated for Securities Fraud after 29% Stock Drop -- Investors Reminded to Contact BFA Law
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
ADMA Shareholder News: ADMA Biologics Investigated for Securities Fraud Over Alleged Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
ADMA Shareholder News: ADMA Biologics Investigated for Securities Fraud Over Alleged Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti and Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
New Strong Sell Stocks for May 14th
ADMA, AMTB and APOG have been added to the Zacks Rank #5 (Strong Sell) List on May 14th, 2026.
Price Targets
Adma Biologics price target lowered to $18 from $21 at Canaccord
$18.00
(was $10.08)
Gary Nachman
·
Canaccord Genuity
Adma Biologics initiated with a Buy at Canaccord
$21.00
(was $10.88)
Canaccord Genuity
Adma Biologics price target lowered to $24 from $30 at Mizuho
$24.00
(was $10.33)
Anthony Petrone
·
Mizuho Securities
H.C. Wainwright Reiterates Buy Rating on ADMA Biologics (ADMA)
$18.00
(was $17.14)
Raghuram Selvaraju
·
H.C. Wainwright
ADMA Biologics (ADMA) PT Raised to $14 at Mizuho
$14.00
(was $10.62)
Anthony Petrone
·
Mizuho Securities
HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $4.5
$4.50
(was $3.88)
H.C. Wainwright
Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $6
$6.00
(was $3.05)
Mizuho Securities
HC Wainwright & Co. Maintains Buy on ADMA Biologics, Lowers Price Target to $4
$4.00
(was $2.17)
H.C. Wainwright